EN DE
STOCK COMPARISON

Abnova Taiwan vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Abnova Taiwan (4133) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 11, 2026.

As of Aug 11, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Abnova Taiwan trades at TWD 21.25 versus a fair value of TWD 8.86 (-58%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).
Abnova Taiwan
4133.TW · TWD · Health Care
-58%
upside to fair value
overvalued
PriceTWD 21.25
Fair ValueTWD 8.86
Quality56/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-44%
upside to fair value
overvalued
Price$496
Fair Value$279
Quality79/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Abnova TaiwanVertex Pharmaceuticals
Valuation
P/E (TTM)28.8×
0.12×P/S (TTM)10.06×
P/B6.59×
EV/EBITDA23.8×
PEG1.72×
0.5%Dividend yield
TWD 0.11Dividend per share
Profitability
1%Net margin36%
12%Operating margin38%
0%Return on equity24%
1%Return on assets12%
Growth
-3%Revenue growth (YoY)8%
-5.2%Avg. growth/yr (3Y)10.6%
-5.1%Avg. growth/yr (5Y)14.2%
Balance & size
Debt / equity0.03×
$40MMarket cap$123B
weakGrowth qualityhealthy

Vertex Pharmaceuticals leads: 1 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Abnova Taiwanof which business quality 56 · market factors 40 Vertex Pharmaceuticalsof which business quality 77 · market factors 65
ProfitabilityMargins and returns on capital today
15
72
Quality GrowthAre margins and returns improving?
15
65
CashflowEarnings quality: real cash, not paper profit
40
79
Fin. StrengthBalance sheet, leverage, solvency risk
99
92
InvestmentDisciplined investing over empire-building
100
58
Low VolatilityCalm price path (market factor)
87
86
MomentumPrice trend over the last 3–12 months (market factor)
26
54
52W MomentumDistance to the 52-week high (market factor)
11
59
Net IssuanceBuybacks instead of dilution
83
82

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Abnova Taiwan

DCF ModelsTWD 10.41
Earnings-BasedTWD 8.54
Dividend DiscountTWD 7.93
MultiplesTWD 11.02
Asset-BasedTWD 13.90
Economic ProfitTWD 8.54

9 of 9 models see the stock below the current price.

Vertex Pharmaceuticals

DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692

18 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Abnova Taiwan
Bear TWD 8.51Fair Value TWD 8.86Bull TWD 9.56
TWD 21.25 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$496 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Abnova Taiwan · Health Care

Quality score56 · above median
Fair value upside-58% · below median

Vertex Pharmaceuticals · Health Care

Quality score79 · Top 25%
Fair value upside-44% · below median

Bottom line

As of Aug 11, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Abnova Taiwan trades at TWD 21.25 versus a fair value of TWD 8.86 (-58%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).

Vertex Pharmaceuticals has the higher quality score (79/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.